Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Braz. j. infect. dis ; 12(1): 20-23, Feb. 2008. tab
Article in English | LILACS | ID: lil-484413

ABSTRACT

Chronic hepatitis C virus (HCV) infection is now the most important cause of liver cirrhosis and hepatocellular carcinoma worldwide. HCV infection prevalence is high among haemophiliacs (39 percent-98 percent), who got infected when received inadequately or non-virus-inactivated large-pool clotting factors concentrates before 1992. Current treatment reduces the probability of developing advanced stages of liver disease. The objective of this study was to evaluate efficacy and safety of the treatment with interferon alpha (IFN) and ribavirin in haemophiliacs. From July 2000 to November 2002, 18 patients were treated with IFN, three million units thrice weekly combined with daily oral doses of 1,000 or 1,250 mg of ribavirin for a minimum of 48 weeks. Eleven patients (61 percent) showed end of treatment virological response, while nine [(50 percent): 95 percent CI: 27-73 percent] showed sustained virological response as defined by undetectable HCV-RNA six months after treatment. All those nine had persistently undetectable HCV-RNA two to four years post-treatment. There was no treatment interruption due to adverse events. Therefore, the rate of sustained virological response was 50 percent, with good tolerance.


Subject(s)
Adolescent , Adult , Female , Humans , Male , Middle Aged , Young Adult , Antiviral Agents/therapeutic use , Hemophilia A/complications , Hepatitis C, Chronic/drug therapy , Interferon-alpha/therapeutic use , Ribavirin/therapeutic use , Antiviral Agents/administration & dosage , Drug Therapy, Combination , Genotype , Hepacivirus/genetics , Interferon-alpha/administration & dosage , RNA, Viral/analysis , Ribavirin/administration & dosage , Treatment Outcome , Young Adult
2.
In. Kowalski, Luiz Paulo; Guimarães, Gustavo Cardoso; Salvajoli, João Victor; Feher, Olavo; Antoneli, Célia Beatriz Gianotti. Manual de Condutas Diagnósticas e Terapêuticas em Oncologia. São Paulo, Âmbito Editores, 3 ed; 2006. p.215-217.
Monography in Portuguese | LILACS | ID: lil-478422
3.
In. Kowalski, Luiz Paulo; Guimarães, Gustavo Cardoso; Salvajoli, João Victor; Feher, Olavo; Antoneli, Célia Beatriz Gianotti. Manual de Condutas Diagnósticas e Terapêuticas em Oncologia. São Paulo, Âmbito Editores, 3 ed; 2006. p.137-140.
Monography in Portuguese | LILACS | ID: lil-478444
6.
In. Fundaçäo Antonio Prudente. Hospital A. C. Camargo. Manual de condutas diagnósticas e terapêuticas em oncologia. Säo Paulo, Ambito Editores, 1996. p.80-84.
Monography in Portuguese | LILACS | ID: lil-180253
7.
Acta oncol. bras ; 13(1/3): 36-41, jan.-dez. 1993.
Article in Portuguese | LILACS | ID: lil-155322

ABSTRACT

A susceptibilidade à infecçäo aumenta dramaticamente quando a contagem periférica de neutrófilos cai abaixo de 500cels/mm3, e particularmente quando abaixo de 100cls/mm3. A rapidez da queda dos granulócitos e a duraçäo da aplasia estäo mais associados com os quadros infecciosos. Culturas de vigilância têm mostrado um valor limitado em predizer uma infecçäo invasiva em pacientes neutropênicos ou com câncer. O isolamento protetor simples em pacientes com granulocitopenia parece näo beneficiar a profilaxia das doenças infecciosas. O uso de descontaminaçäo digestiva seletiva, reduziu infecçöes do trato respiratório e septcemias bacterianas em crianças. O objetivo deste procedimento é eliminar microorganismos patogênicos potenciais, como Enterobacteriaceae, P. aeruginosa e Staphilococci. Os estudos mais recentes têm discutido o uso de Fator estimulador de colonias (CSF) associado a interferon-gama para prevençäo de infecçöes nesses pacientes


Subject(s)
Humans , Granulocyte-Macrophage Colony-Stimulating Factor/therapeutic use , Agranulocytosis , Agranulocytosis/prevention & control , Agranulocytosis/therapy , Agranulocytosis/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL